Description

Mucaltin (mucaltinum) tablets 0.05 №30 vial

Ingredients

Mucaltin tablets contain the active ingredient mucaltinum, which is derived from the Althaea officinalis plant. Other inactive ingredients may include lactose, corn starch, and magnesium stearate.

Dosage

The recommended dosage of Mucaltin tablets is one tablet taken orally three times a day. It is important to follow the instructions provided by your healthcare provider or as indicated on the packaging.

Indications

Mucaltin tablets are commonly used to relieve cough symptoms associated with respiratory conditions such as bronchitis, tracheitis, and pneumonia. The active ingredient mucaltinum helps to soothe the throat and reduce coughing.

Contraindications

Do not use Mucaltin tablets if you are allergic to any of the ingredients. It is important to consult with your healthcare provider before starting any new medication, especially if you have underlying health conditions.

Directions

Take Mucaltin tablets with a full glass of water. Do not crush or chew the tablets. If you have any questions about the proper use of this medication, consult your doctor or pharmacist.

Scientific Evidence

Studies have shown that the active ingredient in Mucaltin tablets, mucaltinum, has mucolytic and expectorant properties that can help to loosen mucus and improve cough symptoms. Research published in the Journal of Ethnopharmacology demonstrated the effectiveness of Althaea officinalis in reducing cough frequency and intensity.

Additional Information

It is important to note that while Mucaltin tablets can provide relief from cough symptoms, they may not be suitable for all individuals. If your symptoms persist or worsen, seek medical advice. Store the tablets in a cool, dry place away from direct sunlight.

Pharmacological Effects: Mucaltinum works by increasing the production of respiratory tract secretions, which helps to thin and loosen mucus, making it easier to expel. This action can provide relief from coughing and improve breathing.

Clinical Trials: A randomized controlled trial published in the International Journal of Chronic Obstructive Pulmonary Disease found that mucolytic agents like mucaltinum can significantly improve lung function and reduce exacerbations in patients with chronic respiratory conditions.